ID

36684

Description

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR); ODM derived from: https://clinicaltrials.gov/show/NCT02293733

Link

https://clinicaltrials.gov/show/NCT02293733

Keywords

Versions (1)
  1. 6/1/19 6/1/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

June 1, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733

English

Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733

1 forms  
Eligibility Criteria
Description

Eligibility Criteria

inclusion criteria:
Description

Inclusion criteria

Data type

boolean

Alias
UMLS CUI [1]
C1512693
nsclc patients with activating mutations of egfr
Description

Non-Small Cell Lung Carcinoma | EGFR Activating Mutation

Data type

boolean

Alias
UMLS CUI [1]
C0007131
UMLS CUI [2]
C2984891
first-line treatment with a tki monotherapy
Description

First line treatment Tyrosine kinase inhibitor

Data type

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C1268567
measurable lesion according to recist 1.1
Description

Measurable lesion

Data type

boolean

Alias
UMLS CUI [1]
C1513041
age> 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
secondary or acquired resistance of egfr tkis according to the jackman criteria
Description

Resistance Secondary EGFR TKI | Resistance Acquired EGFR TKI

Data type

boolean

Alias
UMLS CUI [1,1]
C0013203
UMLS CUI [1,2]
C0175668
UMLS CUI [1,3]
C1443775
UMLS CUI [2,1]
C0013203
UMLS CUI [2,2]
C0439661
UMLS CUI [2,3]
C1443775
patients for whom it was started a tki treatment in first line from january 2010 until june 2012 (patients who received 1 chemotherapy cycle could be included).
Description

First line treatment Tyrosine kinase inhibitor | Chemotherapy cycle Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C1268567
UMLS CUI [2,1]
C1302181
UMLS CUI [2,2]
C1265611
exclusion criteria:
Description

Exclusion Criteria

Data type

boolean

Alias
UMLS CUI [1]
C0680251
patients with small cell carcinoma
Description

Carcinoma, Small Cell

Data type

boolean

Alias
UMLS CUI [1]
C0262584
patients without egfr mutation
Description

EGFR mutation Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C3266992
UMLS CUI [1,2]
C0332197
patients not treated with egfr tki in first line treatment
Description

First line treatment EGFR Tyrosine kinase inhibitor Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C1443775
UMLS CUI [1,3]
C0332197
not measurable lesion to recist 1.1
Description

Measurable lesion Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C0332197
Back to the top of the page

Similar models

Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Inclusion criteria
Item
inclusion criteria:
boolean
C1512693 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma | EGFR Activating Mutation
Item
nsclc patients with activating mutations of egfr
boolean
C0007131 (UMLS CUI [1])
C2984891 (UMLS CUI [2])
First line treatment Tyrosine kinase inhibitor
Item
first-line treatment with a tki monotherapy
boolean
C1708063 (UMLS CUI [1,1])
C1268567 (UMLS CUI [1,2])
Measurable lesion
Item
measurable lesion according to recist 1.1
boolean
C1513041 (UMLS CUI [1])
Age
Item
age> 18 years
boolean
C0001779 (UMLS CUI [1])
Resistance Secondary EGFR TKI | Resistance Acquired EGFR TKI
Item
secondary or acquired resistance of egfr tkis according to the jackman criteria
boolean
C0013203 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C1443775 (UMLS CUI [1,3])
C0013203 (UMLS CUI [2,1])
C0439661 (UMLS CUI [2,2])
C1443775 (UMLS CUI [2,3])
First line treatment Tyrosine kinase inhibitor | Chemotherapy cycle Quantity
Item
patients for whom it was started a tki treatment in first line from january 2010 until june 2012 (patients who received 1 chemotherapy cycle could be included).
boolean
C1708063 (UMLS CUI [1,1])
C1268567 (UMLS CUI [1,2])
C1302181 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Exclusion Criteria
Item
exclusion criteria:
boolean
C0680251 (UMLS CUI [1])
Carcinoma, Small Cell
Item
patients with small cell carcinoma
boolean
C0262584 (UMLS CUI [1])
EGFR mutation Absent
Item
patients without egfr mutation
boolean
C3266992 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
First line treatment EGFR Tyrosine kinase inhibitor Absent
Item
patients not treated with egfr tki in first line treatment
boolean
C1708063 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Measurable lesion Absent
Item
not measurable lesion to recist 1.1
boolean
C1513041 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial